OBI Pharma, Inc.
 | This article does not cite any sources. (May 2018) |
Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
| Type | Public |
| TWSE: 4174(TPEx) | |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan |
Key people | Michael Chang (Chairman) |
| Website | www.obipharma.com |
![[icon]](http://upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png){kind=small} | This section needs expansion. You can help by . (February 2020) |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.
History[]
This company was formerly a subsidiary of Optimer Pharmaceuticals.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was USD 8.50 per share.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
References[]
Categories:
- Biotechnology companies of Taiwan
- Biotechnology companies established in 2002
- Companies based in Taipei
- Taiwanese companies established in 2002